
Résultat de la recherche
9 recherche sur le mot-clé
'xylazine'


C. S. COPELAND ; K. RICE ; K. L. ROCK ; S. HUDSON ; P. STREETE ; A. J. LAWSON ; L. COUCHMAN ; A. HOLLAND ; S. MORLEY | 2024
Dans Addiction (Vol.119, n°7, July 2024) Article : PériodiqueBACKGROUND AND AIMS: Xylazine is a non-opioid sedative which has spread rapidly throughout the US illicit drug supply. This study aimed to describe the spread of xylazine throughout the UK illicit drug supply. METHODS: Xylazine detections in h[...]
This editorial reviews literature on xylazine as well as major clinical considerations for treatment and management of suspected xylazine-involved overdoses and xylazine-related wounds. The clinical presentation and management of xylazine overdo[...]
J. M. BOWLES ; E. C. COPULSKY ; M. K. REED | 2024
Dans International Journal of Drug Policy (Vol.125, March 2024) Article : PériodiqueAmid increasing efforts to understand xylazine-associated harms, examining the potentially catastrophic role of stigma resulting from media outlets framing xylazine as the "zombie drug" is imperative. Zombies are cinematically depicted as soulle[...]
INTRODUCTION: Xylazine, an alpha2-adrenoceptor agonist sedative commonly used in veterinary medicine, is not approved for human use. Nevertheless, xylazine-involved overdose rates have surged in recent years, fueled by an increasingly toxic and [...]
A. C. HOLT ; D. M. SCHWOPE ; K. LE ; J. P. SCHRECKER ; R. HELTSLEY | 2023
Dans Journal of Addiction Medicine (Vol.17, n°4, July-August 2023) Article : PériodiqueOBJECTIVES: Xylazine is a tranquilizer commonly added into the illicit drug supply and a likely contributor to overdoses because it does not respond to naloxone reversal. The objective of this study was to perform a retrospective data analysis o[...]
H. R. SUMNALL ; A. HOLLAND ; A. M. ATKINSON ; C. MONTGOMERY ; J. NICHOLLS ; O. M. MAYNARD | 2025
Dans International Journal of Drug Policy (Vol.136, February 2025) Article : PériodiqueBackground: News media is an important determinant of public understanding of drug policy topics. Recent media reporting around the use of synthetic drugs such as xylazine makes frequent use of non-human metaphors, including reference to the eff[...]
The 2024 National Drug Threat Assessment (NDTA) is a comprehensive strategic assessment of illicit drug threats endangering the United States. DEA's goal in publishing the NDTA is to save American lives by raising awareness and understanding of [...]Nouveauté
The Drug Enforcement Administration (DEA) presents the 2025 National Drug Threat Assessment (NDTA), a comprehensive report that provides a national-level perspective on the threats posed by deadly illicit drugs and the violent transnational crim[...]
J. J. MILLER ; M. YAZDANPANAH ; D. A. COLANTONIO ; D. R. BERIAULT ; S. R. DELANEY | 2024
Dans Clinical Biochemistry (Vol.133-134, December 2024) Article : PériodiqueThe production and use of New Psychoactive Substances (NPS) has skyrocketed over the last decade, causing major challenges for government authorities, public health agencies, and laboratories across the world. NPS are designed to mimic the psych[...]